EMA Recommends Granting a Marketing Authorisation for Camizestrant By Ogkologos - June 5, 2026 149 0 Facebook Twitter Google+ Pinterest WhatsApp It is intended for the treatment of patients with ER-positive, HER2-negative advanced breast cancer with ESR1 mutations Source RELATED ARTICLESMORE FROM AUTHOR Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide Aiming to Support Cancer Research, ESMO Calls on the European Council to Allocate a Budget of at Least €220 Billion to Horizon Europe MOST POPULAR Georgia Middle Schooler Donates All the Proceeds of Her Grand Champion... January 7, 2021 The Nobel Prize winner helping us treat children’s cancers November 8, 2022 Flame of Hope Awards: Celebrating our volunteers April 3, 2023 Cancer in My Community: Expanding Access to Genetic Testing in Mexico September 1, 2020 Load more HOT NEWS OncoArray Links Dozens of DNA Variants to Risk for Common Cancers Spending Review 2021: Promising commitments, but a lot of unanswered questions Radiation Treatment Delivery Improved Using a Visualization of the Invisible Radiation... How to Tell If Cancer Information on Social Media Is “Fake...
